hyperpolarization-activated cyclic nucleotide gated channel generating pacemaker current (HCN4), 12 and membrane adaptor protein ankyrin-B (ANK2). 13 Most recently, a genomewide association study identified a rare missense variant of MYH6, the gene encoding the α-myosin heavy chain, which predisposes affected individuals to SSS. 14 Additionally, several other ion channels and gap junctions have been implicated in the SSS phenotype by knockout mice studies. 15 The majority of familial SSS cases exhibit autosomal dominant inheritance (OMIM_163800), [8] [9] [10] [11] [12] but an autosomal recessive disorder of compound heterozygous SCN5A mutations (OMIM_608567) also exists. 7, 16 Probands carrying compound heterozygous mutations typically manifest severe clinical phenotypes including ECG abnormalities with early onset mostly during the first decade of life 7 and often require the implantation of a pacemaker during infancy. Because familial SSS is relatively rare, the prevalence and functional consequences of these mutations and the epidemiological characteristics have not been extensively studied.
In the present study, we investigated the clinical and genetic backgrounds of 15 families with SSS. We found that familial SSS with SCN5A mutations may represent a subset of cardiac Na channelopathy with strong male predominance and early clinical manifestations.
Methods

Clinical Studies
The study population included 48 individuals from 15 unrelated Japanese families diagnosed with SSS. Family members underwent a physical examination, ECG, an exercise stress test, and Holter recording. SSS or SND was considered if one of the following conditions was recorded at ≥1 occasions when inappropriate for the circumstances: (1) sinus bradycardia, (2) sinus arrest or exit block, and (3) combinations of sinoatrial and atrioventricular conduction disturbances in conjunction with paroxysmal atrial tachyarrhythmias. 17 Long QT syndrome (LQTS) and Brugada syndrome (BrS) associated with SSS were diagnosed using the most recently available respective criteria. 18, 19 Epidemiological data of nonfamilial SSS (n=538) were obtained from the most recent databases of 4 Japanese institutions, in which SSS cases with a family history of pacemaker implantation, sudden death, or underlying structural heart diseases were excluded. This study was approved by a review committee of each institution, and the subjects gave informed consent.
Genetic Screening
All probands and family members who participated in the study gave their written informed consent in accordance with the Declaration of Helsinki and local ethics committees. Genetic analysis was performed on genomic DNA extracted from peripheral white blood cells using standard methods. Coding regions of SCN5A, HCN4, KCNQ1, KCNH2, GJA5, KCNJ3, MYH6, IRX3, and LMNA were amplified by polymerase chain reaction using exon-flanking intronic primers. Primer information for KCNJ3, MYH6, IRX3, and LMNA is available in Table I in the Data Supplement. Direct DNA sequencing was performed using an ABI 3130 genetic analyzer (Life Technologies, Carlsbad, CA). Mutations were validated by screening DNA samples from 200 healthy Japanese volunteers and using public databases (db-SNP and 1000 Genomes).
Biophysical Analysis of SCN5A Mutants
Site-directed mutagenesis was performed using human heart Na channel α-subunit Na v 1.5. The human cell line tsA-201 was transiently transfected with wild-type or mutant SCN5A plasmids, and Na currents were recorded using the whole-cell patch clamp technique as described previously. 20 Further details are available in the Methods in the Data Supplement.
Statistics
Results are presented as means±SE, and statistical comparisons were made using the Student t test to evaluate the significance of differences between means followed by a Bonferroni adjustment for the total number of comparisons. Statistical significance was assumed for P<0.05.
Results
Case Presentations
We genetically screened 48 members of 15 families with SSS (A1-A5 and B1-B10) and identified 6 SCN5A mutations in 5 families (A1-A5; Figures 1 and 2) . The clinical and genetic information of 15 probands and mutation-positive family members (n=14) is shown in Table II in the Data Supplement.
Family A1
A 4-year-old boy (III:2) visited a pediatric clinic to investigate the bradycardia identified during a physical checkup at kindergarten. He had no perinatal problems. Despite a prescription of denopamine, he experienced multiple syncopal episodes and visited a cardiology hospital at the age of 5 years. Holter ECG revealed SSS with a maximum R-R interval of 5.9 s (Figure 2A ), so an epicardial pacemaker was implanted. P wave amplitudes progressively diminished and had disappeared by the age of 12 when the pacemaker generator was replaced. However, atrial pacing could not be achieved even with the use of high voltages ≤6 V, compatible with atrial standstill. Genetic screening revealed 2 novel SCN5A mutations: an in-frame indel mutation 801_803delMSN/insS (c.2401_2409delinsTCC) in exon 15, referred to as MSN/S, and a missense mutation M1880V (c.5638A>G) in exon 28 ( Figure 3 ). Heterozygous MSN/S was also demonstrated in paternal family members (II:1 and III:1) and heterozygous M1880V was observed in maternal family members (I:2, II:2, and III:3), demonstrating that the proband is a compound carrier of 2 distinct SCN5A mutations ( Figure 1 ). There was no family history of SSS or pacemaker implantation, but his mother (II:2) was diagnosed with BrS from the observation of typical type-I ST-segment elevation provoked by the Na channel blocker flecainide ( Figure 2B ). The remaining affected members were asymptomatic and had no sign of cardiovascular diseases.
Family A2
An 18-year-old woman (II:2) was admitted to hospital because of dizziness on standing. Holter ECG recording revealed frequent episodes of sinus arrest with a maximum R-R interval of 7.7 s, so a diagnosis of SSS was made and a pacemaker was implanted. Echocardiography was normal. Her maternal uncle (II:3) died suddenly during running at the age of 35. Genetic screening revealed a missense mutation R219H (c.656G>A) in SCN5A exon 6 of the proband and her asymptomatic mother (II:2; Figure 3 ). This mutation was previously reported in an individual with familial dilated cardiomyopathy (DCM) associated with a third-degree atrioventricular block, ventricular tachycardia, and atrial flutter (AFL). 21
Family A3
A 3-year-old boy (II:2), admitted to hospital because of fever, showed AFL and ventricular tachycardia ( Figure 2C ). Sinus arrest of 5.2 s was evident by Holter ECG recording, and he was diagnosed with SSS. Structural heart diseases were excluded by echocardiography. His mother also showed SSS and AFL. Genetic screening showed that they shared a novel heterozygous 2-bp deletion (c.5355_5354delCT) resulting in a frame shift mutation, L1786fsX2, located in exon 28 of SCN5A (Figure 3 ).
Family A4
A 15-year-old boy (III:5) with bradycardia lost consciousness after a collision during a soccer game. ECG displayed junctional bradycardia (heart rate, 38 beats per minute; maximum R-R interval=5 s) with left axis deviation. Echocardiography revealed dilatation of the left ventricle (left ventricular enddiastolic diameter, 59 mm), but the left ventricular systolic function was normal (ejection fraction, 64%). His brother (III:1), a pacemaker recipient because of SSS, has a dilated right ventricle and has experienced episodes of AFL and ventricular tachycardia. Genetic screening revealed a missense mutation D1275N (c.3823G>A) in SCN5A exon 21, previously linked to DCM with conduction disorder (Figure 3 ). 22 Figure 2 . Electrocardiographic phenotypes. A, Consecutive strips of Holter ECG recording from proband A1-III:2 carrying compound heterozygous SCN5A mutations showed sinus arrest for 5.9 s (at the age of 5). B, His mother A1-II:2 showed covedtype ST-segment elevation in V1 through V2 leads during the flecainide challenge test. C, Paroxysmal atrial flutter (AFL) recorded in the proband A3-II:2. D, QT prolongation (QTc, 522 ms) remains evident in the proband A5-II:2 even after thyroid hormone supplemental therapy. The mutation was identified in his brother (III:1), asymptomatic father (II:1), and younger sister (III:7).
Family A5
Sinus bradycardia and QT prolongation with day-to-day variation (QTc, 450-530 ms) were observed when the proband (II:2) was 22 years old, which were exacerbated after thyroidectomy as a treatment of hyperthyroidism at the age of 36. An electrophysiological study revealed SND (sinus node recovery time, 5.08 s), atrioventricular block (His ventricular, 68 ms), and atrial standstill in addition to QT prolongation (QTc, 522 ms; Figure 2D ), whereas the thyroid function was normally controlled. Her mother (I:2) and son (III:3) showed QT prolongation, while her brother (II:3) had both LQTS and BrS. Genetic screening revealed that the proband and these 3 family members carried an SCN5A missense mutation in exon 28, E1784K (c.5350C>A; Figure 3 ), which is the most common SCN5A mutation in type-3 LQTS (LQT3) associated with multiple clinical phenotypes of LQTS, BrS, and SSS. 20 The proband prophylactically received an implantable cardioverter defibrillator at the age of 36, which discharged appropriately 1 year later during an episode of spontaneous ventricular fibrillation.
Mutation Analysis of Probands and Family Members
Nineteen mutation carriers were identified within the 5 families with SSS (A1-A5; Table II in the Data Supplement). Seven individuals (37%) exhibited SSS, while 7 carriers (37%) were asymptomatic; other carriers showed variable arrhythmias including LQTS, BrS, and AFL without SSS, suggesting that SSS has a considerably reduced penetrance in these families. No mutations were identified in HCN4, KCNQ1, KCNH2, KCNJ3, MYH6, GJA5, and IRX3. Among the SCN5A mutations we found, D1275N 22, 23 and E1784K 20 have previously been well characterized; therefore, we analyzed the functional properties of other mutants.
Functional Characterization of SCN5A Mutations
As shown in Figure 4A , all plasmids, except for L1786fsX2, elicited a robust Na current but the noninactivating late current, which characterizes LQT3 mutations, 24 was not evident. Peak current density measured 24 hours after transfection was significantly reduced in MSN/S, M1880V+MSN/S, R219H, and L1786fsX2 compared with wild type (Figure 4B and 4C). Because L1786fsX2 was nonfunctional, channel properties were further analyzed for M1880V+MSN/S and R219H (biophysical properties of other mutations are shown in Table  III in the Data Supplement). The voltage dependence of activation was significantly shifted in the depolarizing direction (+7.5 mV; P<0.01) in M1880V+MSN/S, and the voltage dependence of steady-state inactivation was significantly shifted in the hyperpolarizing direction in R219H (−11.4 mV; P<0.01; Figure 4D ). Recovery from inactivation was remarkably delayed in R219H ( Figure 4E ). The lower current density, depolarizing shift of the activation curve, hyperpolarizing shift of the inactivation curve, and delayed recovery from inactivation observed in M1880V+MNS/S, R219H, and the nonfunctional channel L1786fsX2 are typical loss-of-function properties of Na channels.
Epidemiological and Genetic Characteristics of Familial SSS
The average age of onset of the probands in our SSS cohort was 35.5±5.4 years (range, 3-65), which was substantially less than that of the 538 cases of sporadic SSS (74.3±0.4 years; P<0.001; Figure 5 ). When the cohort was classified by the presence or absence of SCN5A mutations, the SCN5Apositive subgroup showed an even earlier onset (12.4±4.6 years; n=5) than the negative subgroup (47.0±4.6 years; n=10; P<0.001). To confirm this observation, we searched the literature for descriptions of SSS probands with SCN5A mutations and a family history of SSS and identified 24 cases in addition to the 5 (A1-A5) in our cohort ( Table IV in the Data Supplement). To our surprise, the 29 SSS probands with SCN5A mutations exhibited not only an early onset (20.9±3.4 years) but also a striking male predominance (male: 23/29; 79.3%). If we focus on the SSS subgroup without disease complications such as BrS or LQTS, the tendency of early onset was even more obvious. As shown in the histogram in Figure 5B , the SSS-only subgroup (filled boxes) had a young age of onset (mean age, 7.8±1.9 years; n=11) and a prominent male preponderance (10/11; 91%). These data indicate that the subset of familial SSS with SCN5A mutations has a strong male predominance resembling BrS but exhibits a considerably earlier clinical manifestation. Nevertheless, the same pathophysiological basis of loss-of-function of the cardiac Na channel is shared.
Discussion
We identified 6 SCN5A mutations in 15 familial SSS probands and demonstrated that familial SSS with SCN5A mutations may represent a distinct cardiac Na channelopathy with early onset and male predominance.
SCN5A is the cardiac Na channel gene responsible for the generation and rapid propagation of action potentials in the heart. Mutations in SCN5A have been linked to a wide range of inherited lethal arrhythmias, referred to as cardiac Na channelopathy, including LQT3, 24 BrS, 25 progressive cardiac conduction defect, 26 sudden infant death syndrome, and SSS. To date, ≥27 distinct SCN5A mutations that are causative of SSS have been reported, although some mutation carriers exhibit mixed clinical phenotypes in addition to SSS ( Table  IV in the Data Supplement). [8] [9] [10] Heterologously expressed mutant SCN5A commonly results in a loss of function with reduced (R219H, M1880V+MSN/S) or no (L1786fsX2) Na current density, in conjunction with alterations of biophysical properties (Figure 3) .
The compound heterozygous mutation M1880V+MSN/S results in a channel behavior phenotype that is intermediate between that of M1880V and MSN/S, and functional analysis of the singular mutations suggests that M1880V may have more benign channel properties than MSN/S ( Table III in the  Data Supplement) . However, the proband's mother (A1-II:2), carrying the M1880V allele but not MSN/N, showed BrS, suggesting that the in vivo consequences of M1880V may not be as benign as observed in the heterologous expression system. A similar discrepancy between in vivo and in vitro situations was previously reported in the SCN5A mutation D1275N, which was identified in the A4 family of our present cohort.
Despite the severe conduction disturbance and DCM, the heterologously expressed D1275N channel showed almost normal behavior. 27 Interestingly, cardiomyocytes from mice carrying the human D1275N SCN5A allele display both a decreased current density and late Na current, which is a hallmark of LQT3. 23 Such a mixed biophysical phenotype is observed in association with several SCN5A mutations including E1784K (identified in family A5), the most frequent SCN5A mutation causative of LQTS, BrS, and SSS. 20 Moreover, a negative shift of steady-state inactivation is a common biophysical mechanism underlying the phenotypic overlap of cardiac Na channelopathy. 20 Taken together, the most typical biophysical feature in SCN5A mutations causative of SSS is the loss-offunction property that reduces electric coupling between the sinus node and surrounding atria, resulting in conduction block (exit block). However, a subset of SCN5A mutations associated with SSS display a gain-of-function property characteristic of LQT3, 9, 20 resulting in a reduction of the sinus rate by prolonging the sinus node action potential and disrupting its complete repolarization. 9 Recently, Gosselin-Badaroudine et al 21 identified the R219H mutation in a family with DCM associated with ventricular tachycardia and a third-degree atrioventricular block. They found that the mutant R219H channel selectively permeates protons through the channel pore, which in turn results in severe left ventricular dysfunction and conduction disturbance. By contrast, clinical observations of our R219H carriers (A2-I:2, II:2) were rather benign, with electric abnormalities restricted to the sinus node with no left ventricular dysfunction. Moreover, we observed a reduced peak Na current, a hyperpolarizing shift of steady-state inactivation, and a slowed recovery from inactivation of the R219H mutant channel. However, we were unable to evaluate the proton permeation properties in our experimental system. Such loss-offunction properties are commonly observed in most SCN5A mutations responsible for familial SSS. The reasons for the discrepancy between our findings and those of Gosselin-Badaroudine et al 21 are not clear; however, additional genetic modifiers within SCN5A or other unidentified genes may contribute to the severe clinical and biophysical properties of mutant Na channels.
Autosomal dominant transmission is the most common mode of inheritance in familial SSS, 8, 10, 11 although autosomal recessive transmission has been reported in several severe juvenile cases of congenital SSS. 7, 16 Consistent with previous reports, 4-6 the majority of patients with nonfamilial SSS in the present study are elderly, with both sexes nearly equally affected ( Figure 5 Figure 4 . Whole-cell current recordings of wild-type (WT) and mutant Na channels. A, Representative whole-cell current traces obtained from tsA-201 cells transfected with WT or mutant Na channels. Currents were recorded from a holding potential of −120 mV and stepped to various membrane potentials from −90 to +50 mV for 20 ms. B, Current was normalized to cell capacitance to give a measure of Na current density. There were significant decreases in maximum current density in M1880V+MSN/S and R219H (P<0.05), and in MSN/S and L1786fsX2 (P<0.01) compared with WT. C, Current-voltage relationship of WT and 2 mutant channels (MSN/S+M1880V and R219H). D, Steady-state inactivation and conduction-voltage relationship in MSN/ S+M1880V and R219H. E, Time course of recovery from inactivation at −120 mV. Detailed parameters are provided in Table III in the Data Supplement. mutations are characterized by early onset and a strong male predominance. Male predominance (80%-90%) and prevalence of SCN5A mutations (≈20%) are known features of BrS, 19 which often associates with SND or atrial arrhythmias. 28, 29 Makiyama et al 11 genetically screened 38 BrS probands and identified 4 SCN5A mutation carriers (10.5%), all of which were complicated with bradyarrhythmias including SSS. These data suggest a close relationship between BrS and familial SSS, and our study further supports this notion by demonstrating the prominent male predominance in these 2 disorders.
Nonetheless, there is a clear difference between familial SSS and BrS regarding the age of manifestation. The mean age of the 29 probands of familial SSS with SCN5A mutations in our study were considerably less (20.9±3.4 years) than those affected with BrS, which typically manifests during adulthood at a mean age of around 40 years. Furthermore, it should be noted that only 2 of 24 (8.3%) of the family members of our cohort who were carriers of the mutations exhibited a BrS phenotype even later in their lives (mean age, 34.5±4.1 years), suggesting that penetrance of familial SSS in our cohort was incomplete (67%; 16/24). These data suggest that SND is the earliest electrophysiological manifestation of SCN5A mutation carriers, which may be associated with other arrhythmias such as LQT3, BrS, or DCM under the control of confounding factors including aging, hormones, other genetic variations, and undetermined environmental factors. We have followed up the SSS probands for 7.7±2.1 years ( Table II in the Data Supplement), but longer term follow-up of the mutation carriers and further genetic studies of mutation-negative SSS probands may uncover crucial factors that determine the distinct age-dependent manifestations observed in familial SSS and BrS. Figure 5 . Age of onset and sex difference in probands with nonfamilial and familial sick sinus syndrome (SSS). A, Age of onset of nonfamilial SSS (n=538), SSS probands of our cohort (n=15) including SCN5A mutation negative (n=10) or positive (n=5), and meta-analysis of 29 cases with SCN5A mutations. § and * indicate P<0.001 vs mutation negative, and P<0.001 vs nonfamiliar SSS, respectively. B, Upper histogram shows age of onset in Japanese patients with nonfamilial SSS (n=538; 74.3±0.4 years): male (upper; n=241) and female (lower; n=257). There was no sex difference. Lower histogram shows the age of onset and sex difference in 29 probands with familial SSS. Filled and shaded columns show SSS only (n=11) and SSS with complications including BrS (n=18), respectively. Early onset and male predominance were more apparent in the SSS-only group.
